Exenatide is one of a new class of medications (incretin mimetics) for the treatment of type 2 diabetes mellitus and was approved in April 2005 by the U.S. Food and Drug Administration. We undertook a systematic review and meta-analysis of exenatide therapy compared to both placebo and insulin...

Recently, there has been much discussion about replicability and credibility. By integrating the full research record, increasing statistical power, reducing bias and enhancing credibility, meta-analysis is widely regarded as 'best evidence'. Through Monte Carlo simulation, closely calibrated on...